Status:
COMPLETED
Immunophenotyping of Blast Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From AML and MDS Patients (AML)
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to evaluate the immune profile of blast cells and immune effector cells in paired peripheral whole blood and bone marrow samples from AML and MDS patients by standardize...
Eligibility Criteria
Inclusion
- Age \> 18
- No pregnant woman
- Patient with myelodysplastic syndrome (with excess blasts) or acute myeloid leukemia
- Presence of a monitored serum blastose
- Patient who can obtain free and informed consent (speaks French, no guardianship or curatorship)
Exclusion
- Minor Patient (\< 18 years old)
- Medical or psychological Condition that could interact with the ability to understand the study,
- Pregnant or lactating women,
- Major persons under guardianship or under the protection of justice
- Persons deprived of their liberty by a judicial or administrative decision
- Lack of information and opposition to its participation in the study
Key Trial Info
Start Date :
January 9 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 25 2022
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT03801005
Start Date
January 9 2019
End Date
March 25 2022
Last Update
January 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique - Hopitaux de Marseille
Marseille, France, 13387